Real-time biomedical studies possible through one of the world's largest ocular research centres

Article

Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research.

Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research. As the first research centre in the world to be directly combined with an eye bank, the Ocular Research Centre provides a repository of healthy and diseased ocular tissue for researchers from academic institutions, government organizations and the pharmaceutical industry.

For the first time, researchers can study the complete picture of health through tissue, medical history and family information, which will improve the understanding of underlying health factors leading to vision impairment and blindness. These studies will drive the development of new diagnostic tests and pharmacologic treatments for delaying, stopping and preventing progression of ocular diseases and conditions.

Over the past 30 years, Lions Eye Institute for Transplant & Research has provided 50,000 eyes for research and given the gift of sight through cornea transplantation to more than 30,000 men, women and children worldwide.“The Ocular Research Centre recently established a relationship with Emory University and we look forward to forming relationships with other organizations to accelerate drug innovation, provide timely clinical trials and formalize best practices,” said Jason Woody, Lions Eye Institute for Transplant & Research CEO.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.